Eiger, Daniel
Pondé, Noam F.
Agbor-Tarh, Dominique
Moreno-Aspitia, Alvaro
Piccart, Martine
Hilbers, Florentine S.
Werner, Olena
Chumsri, Saranya
Dueck, Amylou
Kroep, Judith R.
Gomez, Henry
Láng, István
Rodeheffer, Richard J.
Ewer, Michael S.
Suter, Thomas
de Azambuja, Evandro
Article History
Received: 13 September 2019
Revised: 11 February 2020
Accepted: 24 February 2020
First Online: 16 March 2020
Ethics approval and consent to participate
: The institutional review board at each participating centre approved the ALTTO trial protocol. All patients provided written informed consent, as previously reported.<sup>5</sup>
: The authors declare that all data supporting the findings of this study are available within the article and its Supplementary Information files or are available from the corresponding author upon reasonable request.
: D.E.: funding for his ESMO fellowship (2018–2019) provided by Novartis; research grant for his institute: Roche/GNE, Radius, Astra-Zeneca, Lilly, MSD, Novartis, Synthon, Servier, and Pfizer; N.F.P.: honoraria: MundiPharma, Astrazeneca; travel grants: Novartis, Astrazeneca, MundiPharma, Roche; D.A.T.: none; A.M.A.: none; M.P.: Board Member (Scientific Board): Oncolytics, Radius; Consultant (honoraria): AstraZeneca, Camel-IDS, Crescendo Biologics, Debiopharm, G1 Therapeutics, Genentech, Huya, Immunomedics, Lilly, Menarini, MSD, Novartis, Odonate, Oncolytics, Periphagen, Pfizer, Roche, Seattle Genetics; Research grants to her Institute: AstraZeneca, Lilly, MSD, Novartis, Pfizer, Radius, Roche-Genentech, Servier, Synthon; Speakers bureau/stock ownership: none; F.H.: research grant for her Institute (for the conduct of the ALTTO trial): GSK, Novartis; O.W.: employee of Novartis Pharma AG; S.C.: Research grant from Merck & Co. and Array BioPharma. Consultation/Advisory Board from Novartis, Syndax Pharmaceuticals Inc., Puma Biotechnology, and Immunomedics Incs.; A.D.: Research funding from GSK during the study; J.R.K.: none; H.G.: received honoraria as speaker from AstraZeneca, Roche, BMS, and Novartis; I.L.: none; R.J.R.: none; M.S.E.: ownership or stock/financial holdings: none; Book royalties: Elsevier and Peoples Medical Publishing House; Consulting agreements with Boehringer-Ingelheim, Bayer, Merck, and Daiichi Sankyo; T.S.: none; E.A.: honoraria and advisory board: Roche/GNE; travel grants: Roche/GNE, GSK/Novartis; co-principal investigator of the LORELEI trial (NCT02273973); research grant for his institute: Roche/GNE, Radius, Astra-Zeneca, Lilly, MSD, Novartis, Synthon, Servier, and Pfizer.
: Novartis has funded all the statistical analysis for ALTTO Cardiac. The ALTTO trial was supported by GlaxoSmithKline (GSK) and the National Cancer Institute of the National Institutes of Health under Award Numbers U10CA180821 and U10CA180882 to the Alliance for Clinical Trials in Oncology, CA025224 to the legacy North Central Cancer Treatment Group (NCCTG), and CA077202 to the National Cancer Information Center (NCIC) Clinical Trials group. NCIC CTG participation was also supported by the Canadian Cancer Society Research Institute under Award Number 015469 and 021039.